IMV Inc. Presents New Positive Data from Phase 2 Monotherapy Arm of Its Decide1 Trial in Advanced Ovarian Cancer and Continued Duration of Clinical Benefits to Patients with Progression Free Survival

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology
corporation, today announced that investigators shared new positive data
for its DeCidE1 (DPX-Survivac with low dose Cyclophosphamide and
Epacadostat) clinical trial at the 2019
American Society for Clinical Oncology (ASCO) Annual Meeting.

These new data are from the ongoing Phase 1b/2 trial evaluating the
safety and efficacy of IMVa??s lead candidate DPX-Survivac and
intermittent low-dose cyclophosphamide (CPA), with and without Incytea??s
IDO1 enzyme inhibitor epacadostat, in patients with advanced recurrent
ovarian cancer. New data from evaluable patients from the phase 2
monotherapy arm of the trial indicated the potential for DPX-Survivac to
impact solid tumor growth in hard to treat ovarian cancer patients.
Longer-term follow-up from the phase 1b portion of the trial continued
to demonstrate that the levels of survivin-specific T cells in the blood
of patients a?? a measure of DPX-Survivaca??s novel mechanism of action
(MOA) a?? correlated with durable clinical benefits.

Updated Clinical Data for DeCidE1

In a poster
presentation, Janos L. Tanyi, M.D., Ph.D., Assistant Professor of
Obstetrics and Gynecology at the Hospital of the University of
Pennsylvania, provided an update on the clinical results from the first
patients enrolled in the phase 2 monotherapy cohort.
have enrolled 19 of 28 participants to date:

Of seven patients evaluable at data cut-off in the monotherapy arm,
five showed signs of treatment benefits, including reduction of target
lesions in two patients, while two patients progressed.

Within the group of four patients with low tumor burden a?? a potential
predictor of response a?? three showed stable diseases including two
reductions in tumor burden continuing the positive trend seen in
earlier results.

All subjects evaluable for T cell responses (five of five) showed
survivin specific T cell activation in the blood, four of five showed
a robust response. IHC analysis for tumor infiltration is ongoing

Treatments have been well tolerated.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Август 2022    »